• Subscribe
  • Magazines
  • About
  • Contact
  • Advertise
Friday 4 July 2025
  • zh-hant 中文
  • ja 日本語
  • en English
IAG
Advertisement
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
    • Africa
    • Australia
    • Cambodia
    • China
    • CNMI
    • Europe
    • Hong Kong
    • India
    • Japan
    • Laos
    • Latin America
    • Malaysia
    • Macau
    • Nepal
    • New Zealand
    • North America
    • North Korea
    • Philippines
    • Russia
    • Singapore
    • South Korea
    • Sri Lanka
    • Thailand
    • UAE
    • Vietnam
  • Events
  • Contributors
  • SUBSCRIBE FREE
  • 中文
No Result
View All Result
IAG
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
    • Africa
    • Australia
    • Cambodia
    • China
    • CNMI
    • Europe
    • Hong Kong
    • India
    • Japan
    • Laos
    • Latin America
    • Malaysia
    • Macau
    • Nepal
    • New Zealand
    • North America
    • North Korea
    • Philippines
    • Russia
    • Singapore
    • South Korea
    • Sri Lanka
    • Thailand
    • UAE
    • Vietnam
  • Events
  • Contributors
  • SUBSCRIBE FREE
  • 中文
No Result
View All Result
IAG
No Result
View All Result

MUST: Funding equal to LESS THAN ONE SINGLE DAY of Macau’s 2019 casino GGR would be enough to develop, produce 30 million doses of COVID-19 vaccine candidate

Andrew W Scott and Ben Blaschke by Andrew W Scott and Ben Blaschke
Tue 4 Aug 2020 at 17:43
MUST: Funding equal to LESS THAN ONE SINGLE DAY of Macau’s 2019 casino GGR would be enough to develop, produce 30 million doses of COVID-19 vaccine candidate

Professor Zhang Kang explains how the team’s vaccine attacks the Receptor Binding Domain (RBD) of the virus protein rather than the whole spike.

83
SHARES
1.3k
VIEWS
Print Friendly, PDF & Email

Scientists responsible for developing what they describe as a hugely promising COVID-19 vaccine candidate say they can complete human trials and produce 30 million doses by January 2021 on less than a single day’s worth of Macau 2019 casino revenue.

The revelations came at a press conference at the Faculty of Medicine at Macau University of Science and Technology (MUST) on Tuesday. The press conference was led by Professor Zhang Kang in Macau, and Professor Manson Fok, Dean of the Faculty, who appeared from Hong Kong by video.

The vaccine, announced last week by a team comprising researchers from MUST, in collaboration with Hong Kong Polytechnic University (PolyU), is seen as a leading candidate for mass production after what the researchers describe as exceptional results during early clinical trials. In particular, it induced a “potent functional antibody response” in immunized mice, rabbits and monkeys with those antibodies subsequently neutralizing the virus during laboratory studies by effectively blocking it from binding with cells in the host.

According to key scientists involved, the candidate vaccine is now ready to enter Phase II and Phase III trials which, if all goes well, could see the first 30 million doses manufactured and ready for distribution by late January.

However, at the press conference, it was revealed the project was at risk of stalling over a shortfall in funding. Speaking of the world’s largest casino hub, Professor Fok estimated HK$600 million (US$77 million), equivalent to 77% of one day of Macau casino revenue based on 2019 GGR, or just two days’ worth of gaming taxes collected by the Macau SAR Government, would be needed to develop and produce 30 million doses of the vaccine.

Journalists at Tuesday’s press conference.

The team revealed it had been knocked back in February after applying to the Macau government for funding of just MOP$500,000 (US$62,500), with Professor Fok indicating the government had not been convinced at the time that development of a vaccine was a realistic goal.

According to the MUST team, the cost of the collaborative research, which has involved more than 100 scientists from Macau, Hong Kong and mainland China, is already in the “tens of millions of US dollars” – all of it sourced from the internal resources of eight institutions involved.

But the team is also adamant their vaccine ranks among the most effective, perhaps even the most effective, of the more than 150 vaccine candidates currently being studied globally.

“From a conceptual standpoint, we think this will be a highly effective vaccine with a very low level of side effects,” said Professor Zhang, one of the team’s leaders.

According to Zhang, the team’s vaccine stands out from most others because it only attacks the Receptor Binding Domain (RBD) of the protein rather than the whole protein spike, therefore creating more effective antibodies.

The vaccine is also a standout because it utilizes recombinant DNA, such as that already used in the HPV vaccine widely used to combat various forms of cancer and genital warts. The technology is already readily available and used in manufacturing facilities around the world.

L to R: Dean Fok appearing by video alongside Professor Zhang Kang.

Zhang said the team initiated development of its vaccine shortly after Chinese New Year, with Phase I testing showing no side effects. They are also encouraged by the fact that the vaccine requires administration of an extremely small dose – around 20 micrograms or 1/10th the size of a sesame seed.

Notably, Zhang says the vaccine should even be able to treat those already sick with COVID-19.

The team is now waiting to progress to the next step, Zhang said, where it plans to run Phase II and Phase III trials in humans concurrently to expedite the process.

“We are very confident from our results in the animal studies of its worth,” he said.

Fok added, “Normally human trials to deployment is one-and-a-half to two years,” but pointed to the fact that COVID-19 is not a normal situation. “So far the vaccine has shown strong antibody response, no complications, a significant half-life and it will be very cost effective.”

Macau University of Science and Technology.

Fok did, however, note the vaccine could not be produced locally due to the absence of a vaccine facility in Macau, and a lack of testing capacity in mainland China due to a number of other candidate vaccines being tested. Instead, the MUST team has agreed to conduct a pilot manufacturing program with a partner in Taiwan, which they say has the capability to produce at least 30 million doses in a matter of weeks.

As previously reported by IAG, 8 million of those would be reserved for the people of Macau and Hong Kong. The team, Fok claimed, wants to “produce a vaccine for all of humanity.

“This is a global problem and needs a global solution,” he said.

RelatedPosts

Hong Kong to launch “Southbound Travel for Guangdong Vehicles” scheme, no immediate plans for Macau

Hong Kong to launch “Southbound Travel for Guangdong Vehicles” scheme, no immediate plans for Macau

Wed 2 Jul 2025 at 18:10
Team Spirit

IAG announces Light & Wonder, Angel and Aristocrat Gaming as sponsors of Macau After Dark at Vasco – Bar & Lounge on Monday 7 July

Wed 2 Jul 2025 at 15:33
Macau Legend says no concerns over ability to continue after reaching agreement with lenders to defer HK$2.1 billion in looming repayments

Macau Legend says no concerns over ability to continue after reaching agreement with lenders to defer HK$2.1 billion in looming repayments

Wed 2 Jul 2025 at 06:19
Macau GGR comes in at MOP$18.9 billion in April, up 1.7% year-on-year

JP Morgan: Macau GGR surge seemingly sparked by direct VIP, ultra-premium mass gaming customers

Tue 1 Jul 2025 at 18:15
Load More
Tags: Chinacovid-19Hong KongHong Kong Polytechnic UniversityMacauMacau University of Science and TechnologyMUSTProfessor Manson FokProfessor Zhang KangVaccination
Share53Share4
Andrew W Scott and Ben Blaschke

Andrew W Scott and Ben Blaschke

A former sports journalist in Sydney, Australia, Ben has been Managing Editor of Inside Asian Gaming since early 2016. He played a leading role in developing and launching IAG Breakfast Briefing in April 2017 and oversees as well as being a key contributor to all of IAG’s editorial pursuits.

Born in Australia, Andrew is a gaming industry expert and media publisher, commentator and journalist who moved to Hong Kong in 2005 and then Macau in 2009, when he founded O MEDIA, one of Macau’s largest media companies and parent company of Inside Asian Gaming.

Current Issue

Editorial – An inconvenient truth

Editorial – An inconvenient truth

by Ben Blaschke
Fri 27 Jun 2025 at 15:21

It’s understandable that political observers, academics and members of the public in greenfield jurisdictions would express caution around the legalization...

Light & Wonder’s Siobhan Lane

Light & Wonder’s Siobhan Lane

by Ben Blaschke
Fri 27 Jun 2025 at 15:19

Siobhan Lane, Light & Wonder’s highly experienced CEO of Gaming, speaks to Inside Asian Gaming about the company’s ongoing transformation...

Honesty is the best policy

Honesty is the best policy

by Ben Blaschke
Fri 27 Jun 2025 at 14:13

The Thailand Entertainment Complex Roundtable brought industry stakeholders, politicians and supporters of the government’s Entertainment Complex Bill face to face...

Sri Lanka’s casino industry

Sri Lanka’s casino industry

by Shaun McCamley
Fri 27 Jun 2025 at 13:36

Industry veteran Shaun McCamley delves into the complex history of Sri Lanka’s casino industry at a time when the country...

Evolution Asia
Your browser does not support HTML5 video.
Aristocrat
GLI
Nustar
SABA
Mindslot
Solaire
Hann
Tecnet
NWR
Jumbo
568Win

Related Posts

Wynn Al Marjan Island releases first renderings of uber-luxury Enclave suite and apartment offering

Wynn Al Marjan Island releases first renderings of uber-luxury Enclave suite and apartment offering

by Ben Blaschke
Fri 4 Jul 2025 at 05:59

Wynn Resorts has released first images of its elite suite and apartment offering at Wynn Al Marjan Island, to be known as Enclave and located on the uppermost levels of the UAE integrated resort. According to information published overnight, the...

The 2024 Asian Gaming Power 50

Bally’s ready to pull out of Star rescue deal if AUSTRAC issues monster fine

by Ben Blaschke
Fri 4 Jul 2025 at 05:37

US casino operator Bally’s Corp may have to withdraw from its multi-million-dollar rescue of Star Entertainment Group should the embattled Australian firm be hit with a massive fine by AML watchdog AUSTRAC. Bally’s chairman Soo Kim made the revelation –...

Grand Korea Leisure books US$11.4 million profit in 1Q25 on higher casino sales, better margins

Grand Korea Leisure reports sequential gain but year-on-year decline in casino revenue to US$25.5 million

by Newsdesk
Fri 4 Jul 2025 at 04:52

Foreigner-only casino operator Grand Korea Leisure (GKL) reported casino revenue of KRW34.8 billion (US$25.5 million) in June, representing a 13.6% increase over May although down 6.0% compared with the same month last year. The sequential increase follows a similar trend...

Inside Thai IRs

Thailand’s opposition party, civic groups petition government to withdraw casino bills

by Ben Blaschke
Thu 3 Jul 2025 at 14:32

Thailand’s opposition People’s Party has joined a coalition of civic groups in calling for the government to withdraw the two bills that would legalize land-based and online casino style gambling across the country. According to The Bangkok Post, the groups...



IAG

© 2005-2024
Inside Asian Gaming.
All rights reserved.

  • SUBSCRIBE FREE
  • NEWSFEED
  • MAG ARTICLES
  • VIDEO
  • OPINION
  • TAGS
  • REGIONAL
  • EVENTS
  • CONSULTING
  • CONTRIBUTORS
  • MAGAZINES
  • ABOUT
  • CONTACT
  • ADVERTISE
  • 中文

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • 中文
  • Subscribe
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
  • Events
  • Contributors
  • Magazines
  • Advertise
  • Contact
  • About
  • Home for G2E Asia

© 2005-2024
Inside Asian Gaming.
All rights reserved.

  • 中文
  • English